GET THE APP

Gemcitabine Cardiotoxicity: Two Case Report and Review of the Literature

Clinical Oncology: Case Reports.

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Gemcitabine Cardiotoxicity: Two Case Report and Review of the Literature

Gemcitabine is a chemotherapy treatment that is generally well tolerated, also in elderly patients. In Phases 1 and 2 clinical studies, there was no increased risk of cardiac toxicity. However, in our clinical practice, we have managed two patients in their nineties with cardiovascular events on gemcitabine : one patient with a heart attack and arrhythmia, the other patient in heart decompensation on a paroxysmal arrhythmia. In the literature, there are 15 cases of cardiovascular events on gemcitabine monotherapy and 6 cases on gemcitabine in combination with a platinum salt. The cardiotoxicity of gemcitabine in the elderly is underestimated due to comorbidities and multidrug therapy. Gemcitabine may be a potential cause although the exact mechanism remains unknown. At-risk patients could be targeted for adaptation of infusion modalities by reducing volumes, increasing surveillance and more systematic data reporting.

Special Features

Full Text

View

Track Your Manuscript

Media Partners

Associations